Bryan Johnson, Silicon Valley's anti-aging advocate, has ceased his five-year use of rapamycin, citing risks like disrupted lipid metabolism and insulin resistance. The tech entrepreneur, known for his $2 million annual longevity regimen, called the decision a pivotal shift, reflecting the evolving science and risks in the experimental pursuit of extending human lifespan.